deschloroketamin (DCK), also known as 2'-Oxo-PCM, is a dissociative anesthetic that belongs to the arylcyclohexylamine class of compounds. It is chemically related to ketamine but differs slightly in its molecular structure by the absence of one chlorine atom. Despite this seemingly small structural change, DCK has distinct pharmacological properties and may produce different effects and durations of action.
Like ketamine and similar dissociative compounds, DCK primarily acts as an NMDA (N-methyl-D-aspartate) receptor antagonist. By blocking these receptors, it alters the way the brain processes sensory information, pain signals, and perception. This mechanism can lead to dissociation, changes in awareness, altered thinking, and reduced perception of pain.
Originally, DCK was developed and studied for scientific research into the effects of NMDA receptor antagonists. Unlike ketamine, however, it has not been approved as a medication for treating any medical condition in humans. Most information about DCK comes from laboratory research, case reports, and limited scientific studies rather than large-scale clinical trials.
The effects of deschloroketamine may vary depending on the individual, but reported experiences can include:
Altered perception of time and space
Feelings of detachment from the body or surroundings (dissociation)
Reduced sensitivity to pain
Changes in mood and cognition
Impaired coordination and judgment
Because DCK has not undergone extensive clinical testing, its long-term safety profile remains unclear. Researchers and healthcare professionals caution that use outside of controlled research settings may carry significant risks, including confusion, accidents, psychological distress, cardiovascular effects, and the potential for dependence or misuse.
In many countries, the legal status of deschloroketamine varies. Some jurisdictions regulate or prohibit its possession and distribution, while others may classify it differently depending on local drug laws. Anyone seeking information about DCK should consult the relevant regulations in their country and rely on reputable scientific and medical sources.
Overall, deschloroketamine is best understood as a research chemical with dissociative properties that is chemically related to ketamine but is not an approved therapeutic medication. Ongoing scientific research is needed to better understand its pharmacology, potential applications, and safety profile.
What Is Deschloroketamine (DCK)?
